The BORIS protein expression was conducted by immunohistochemical analysis to identify the BORIS mutations in breast cancer progression and to evaluate the relationship between BORIS mutations corresponding to their protein expression with various clinicopathological variables of breast cancer patients. This evidence concerns the gene CTCFL and breast carcinoma.